---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006851"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:16:52.389498+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aclaris reports Q1 net loss $15.1M, cash runway extended to H1 2028; multiple pipeline milestones ahead

## Summary
- Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.
- Cash runway extended through first half of 2028, fully funding preclinical and clinical plans.
- Bosakitug Phase 2 in atopic dermatitis to start Q2 2025; seeking partners for respiratory indications.
- ATI-2138 Phase 2a AD top line results expected June 2025; ATI-052 IND cleared, Phase 1 starting Q2 2025.
- Jesse W. Hall appointed CMO; Sun Pharma injunction lifted, offering potential non-dilutive financing.

## SEC filing metadata
- accession: 0001558370-25-006851
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/0001558370-25-006851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006851
- JSON: https://secwatch.observer/filing/0001558370-25-006851.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.